[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512993":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":42,"collaborators":47,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Cystinose Stiftung","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Children, adolescents and young adults with cystinosis and their parents",null,"Depending on the patient's age, different HrQoL aspects are more relevant in cystinosis patients and their families. Therefore, a division based on age groups is needed to measure and interpret HrQoL measures successfully:\n\nAge group stratification will include young patients aged 8-12, 13-17 and 18-26 for a self-reported version and children and adolescents aged 0-4, 5-7, 8-12, 13-17, 18-26 for a parent-reported version.",[13],{"name":14,"affiliation":15,"role":16},"Julia Hannah Quitmann, PD Dr.","Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany","STUDY_DIRECTOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+49 (0) 40 7410 52789","j.quitmann@uke.de",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Katharina Hohenfellner, PD Dr. med.","+49 (0861) 70532262","Katharina.Hohenfellner@ro-med.de",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"University Medical Center Hamburg-Eppendorf | Center for Psychosocial Medicine | Department of Medical Psychology","RECRUITING","Hamburg","20246","Germany","DE",{"type":35,"coordinates":36},"Point",[37,38],9.99302,53.55073,{"lat":38,"lon":37},[41],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":46,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Julia Hannah Quitmann","Principal Investigator","Universitätsklinikum Hamburg-Eppendorf",[48,51],{"name":49,"class":50},"Cystinosis Research Network","UNKNOWN",{"name":52,"class":50},"Leben eben! Cystinose-Selbsthilfe e.V.","100512993","development-of-health-related-quality-of-life-instrument-for-patients-with-cystinosis-100512993",false,"NCT05959668","Development of Health-related Quality of Life Instrument for Patients With Cystinosis","Development of a Patient-reported Outcome to Measure the Health-related Quality of Life of Children, Adolescents and Young Adults With Cystinosis.","QUALIFY","In all study phases, patient recruitment follows these inclusion criteria:\n\nPatients will be asked to participate in the study if they meet the following inclusion criteria:\n\n* Children, adolescents, and young adults aged 8-26 years (and at least one of their parents) and further parents only of children aged 0-7\n* patients have a confirmed diagnosis of cystinosis\n* patients have a sufficient knowledge of the German\u002F English\u002F French or Spanish language to participate in focus interviews and complete questionnaires\n* the informed consent of legal guardian and assent from the patient (if older than eight years) was given\n\nExclusion criteria:\n\n* severe cognitive impairment\n* other severe illnesses that strongly determine everyday life","ALL","8 Years","26 Years",{"count":65,"type":66},300,"ESTIMATED","OBSERVATIONAL","Cystinosis is a rare congenital, inherited metabolic disorder that results in the storage of cystine in the cells of many organs of the body. In the infantile nephropathic form of the disease, only the kidney is initially affected by a loss of function, which progresses if untreated and ends in terminal renal failure by early school age. With the prolonged survival of patients due to medication and renal replacement therapy, further loss of function may occur during the course of the disease, especially in the eyes, muscles, endocrine organs and central nervous system.\n\nThe quality of life of children with cystinosis is an under-researched topic. The results of the studies available so far show that the young patients and their families report a reduced quality of life and sometimes behavioral problems.\n\nTo date, there are no disease specific patient reported outcome measures (PROMs) to measure the quality of life of patients with cystinosis. The aim of the study is to develop a PROM for this target group in several languages (German, English, Spanish and French) from different countries (Germany, United States, Spain, France). The PROM will focus on quality of life and will be developed for children, adolescents, and young adults including parent-report of parents with children aged 0 to 26 years.",[70],"Cystinosis",[72,70,73],"Health-related quality of life","Patient-reported outcome measure","2024-08-20",{"date":76,"type":77},"2024-08-22","ACTUAL",{"date":79,"type":77},"2022-05-01",{"date":81,"type":66},"2025-05-31",{"name":5,"class":6},1]